ID

20692

Descrizione

Lantus Versus Levemir Treat-To-Target; ODM derived from: https://clinicaltrials.gov/show/NCT00405418

collegamento

https://clinicaltrials.gov/show/NCT00405418

Keywords

versioni (1)
  1. 11/03/17 11/03/17 -
Caricato su

11 marzo 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Diabetes Mellitus, Type 2 NCT00405418

Inglese

Eligibility Diabetes Mellitus, Type 2 NCT00405418

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes for at least 1 year
Descrizione

Diabetes Mellitus, Non-Insulin-Dependent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0011860
insulin naïve
Descrizione

Insulin naive

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0021641
UMLS CUI [1,2]
C0919936
treated with stable doses of oral antidiabetics for at least 3 months prior to study start, including at least metformin (at least 1g/day)
Descrizione

Antidiabetics Oral Dose Stable | Metformin U/day

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0935929
UMLS CUI [1,2]
C1527415
UMLS CUI [1,3]
C0178602
UMLS CUI [1,4]
C0205360
UMLS CUI [2,1]
C0025598
UMLS CUI [2,2]
C0456683
7% ≤ hba1c ≤ 10.5 %
Descrizione

Glycosylated hemoglobin A Percentage

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0019018
UMLS CUI [1,2]
C0439165
body mass index (bmi) < 40 kg/m²
Descrizione

Body mass index

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1305855
ability and willingness to perform blood glucose monitoring using a blood glucose meter and to use a patient diary
Descrizione

Blood Glucose Self-Monitoring Blood glucose meter Able | Blood Glucose Self-Monitoring Blood glucose meter Willing | Subject Diary Use Able | Subject Diary Use Willing

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0005803
UMLS CUI [1,2]
C0472226
UMLS CUI [1,3]
C0085732
UMLS CUI [2,1]
C0005803
UMLS CUI [2,2]
C0472226
UMLS CUI [2,3]
C0600109
UMLS CUI [3,1]
C3890583
UMLS CUI [3,2]
C0457083
UMLS CUI [3,3]
C0085732
UMLS CUI [4,1]
C3890583
UMLS CUI [4,2]
C0457083
UMLS CUI [4,3]
C0600109
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
type 1 diabetes
Descrizione

Diabetes Mellitus, Insulin-Dependent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0011854
current or previous use of insulin (except for previous treatment of gestational diabetes or brief treatment with insulin for less than 1 week)
Descrizione

Insulin | Therapeutic procedure Gestational Diabetes | Insulin Therapeutic procedure Brief

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021641
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0085207
UMLS CUI [3,1]
C0021641
UMLS CUI [3,2]
C0087111
UMLS CUI [3,3]
C1879313
treatment with glucagon-like peptide (glp)-1 receptor agonists or with dipeptidyl peptidase (dpp)-iv inhibitors
Descrizione

Glucagon-Like Peptide-1 Receptor agonists | Dipeptidyl-Peptidase IV Inhibitors

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0378073
UMLS CUI [1,2]
C0243192
UMLS CUI [2]
C1827106
active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (an optic fundus examination should have been performed in the 2 years prior to study entry)
Descrizione

Proliferative diabetic retinopathy | Light Coagulation | Operative Surgical Procedures | Retinal Disease Unstable Rapidly progressive | Slit lamp fundus examination

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0154830
UMLS CUI [2]
C0023694
UMLS CUI [3]
C0543467
UMLS CUI [4,1]
C0035309
UMLS CUI [4,2]
C0443343
UMLS CUI [4,3]
C1838681
UMLS CUI [5]
C1444586
pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraceptive method)
Descrizione

Pregnancy | Childbearing Potential Pregnancy test negative | Childbearing Potential Contraceptive methods

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0427780
UMLS CUI [3,1]
C3831118
UMLS CUI [3,2]
C0700589
breast-feeding
Descrizione

Breast Feeding

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0006147
history of hypersensitivity to the study drugs or to drugs with a similar chemical structure
Descrizione

Hypersensitivity Investigational New Drugs | Hypersensitivity Pharmaceutical Preparations Chemical Structure Similar

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0013227
UMLS CUI [2,3]
C0220807
UMLS CUI [2,4]
C2348205
treatment with systemic corticosteroids in the 3 months prior to study entry
Descrizione

CORTICOSTEROIDS FOR SYSTEMIC USE

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3653708
treatment with any investigational product in the 2 months prior to study entry
Descrizione

Investigational New Drugs

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0013230
likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
Descrizione

Probability Illicit drug use Patient need for

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0033204
UMLS CUI [1,2]
C0281875
UMLS CUI [1,3]
C0686904
clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult
Descrizione

Cardiovascular Disease | Liver disease | nervous system disorder | Endocrine System Disease | Disease Major Protocol Compliance Difficulty | Disease Major Research results Difficulty

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0007222
UMLS CUI [2]
C0023895
UMLS CUI [3]
C0027765
UMLS CUI [4]
C0014130
UMLS CUI [5,1]
C0012634
UMLS CUI [5,2]
C0205164
UMLS CUI [5,3]
C0525058
UMLS CUI [5,4]
C0332218
UMLS CUI [6,1]
C0012634
UMLS CUI [6,2]
C0205164
UMLS CUI [6,3]
C0683954
UMLS CUI [6,4]
C0332218
impaired hepatic function as shown by alamine aminotransferase (alt) and/or aspartate aminotransferase (ast) greater than three times the upper limit of normal range at study entry
Descrizione

Liver Dysfunction | Alanine aminotransferase increased | Aspartate aminotransferase increased

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0086565
UMLS CUI [2]
C0151905
UMLS CUI [3]
C0151904
impaired renal function as shown by serum creatinine ≥ 1.5 mg/dl (≥ 133 μmol/l) in men and ≥ 1.4 mg/dl (124 μmol/l) in women at study entry
Descrizione

Renal Insufficiency | Creatinine measurement, serum | Gender

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C0201976
UMLS CUI [3]
C0079399
history of drug or alcohol abuse in the last year
Descrizione

Substance Use Disorders

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0038586
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Descrizione

Study Subject Participation Status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348568
Ritorna all'inizio della pagina

Similar models

Eligibility Diabetes Mellitus, Type 2 NCT00405418

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes for at least 1 year
boolean
C0011860 (UMLS CUI [1])
Insulin naive
Item
insulin naïve
boolean
C0021641 (UMLS CUI [1,1])
C0919936 (UMLS CUI [1,2])
Antidiabetics Oral Dose Stable | Metformin U/day
Item
treated with stable doses of oral antidiabetics for at least 3 months prior to study start, including at least metformin (at least 1g/day)
boolean
C0935929 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C0205360 (UMLS CUI [1,4])
C0025598 (UMLS CUI [2,1])
C0456683 (UMLS CUI [2,2])
Glycosylated hemoglobin A Percentage
Item
7% ≤ hba1c ≤ 10.5 %
boolean
C0019018 (UMLS CUI [1,1])
C0439165 (UMLS CUI [1,2])
Body mass index
Item
body mass index (bmi) < 40 kg/m²
boolean
C1305855 (UMLS CUI [1])
Blood Glucose Self-Monitoring Blood glucose meter Able | Blood Glucose Self-Monitoring Blood glucose meter Willing | Subject Diary Use Able | Subject Diary Use Willing
Item
ability and willingness to perform blood glucose monitoring using a blood glucose meter and to use a patient diary
boolean
C0005803 (UMLS CUI [1,1])
C0472226 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
C0005803 (UMLS CUI [2,1])
C0472226 (UMLS CUI [2,2])
C0600109 (UMLS CUI [2,3])
C3890583 (UMLS CUI [3,1])
C0457083 (UMLS CUI [3,2])
C0085732 (UMLS CUI [3,3])
C3890583 (UMLS CUI [4,1])
C0457083 (UMLS CUI [4,2])
C0600109 (UMLS CUI [4,3])
Item Group
C0680251 (UMLS CUI)
Diabetes Mellitus, Insulin-Dependent
Item
type 1 diabetes
boolean
C0011854 (UMLS CUI [1])
Insulin | Therapeutic procedure Gestational Diabetes | Insulin Therapeutic procedure Brief
Item
current or previous use of insulin (except for previous treatment of gestational diabetes or brief treatment with insulin for less than 1 week)
boolean
C0021641 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C0085207 (UMLS CUI [2,2])
C0021641 (UMLS CUI [3,1])
C0087111 (UMLS CUI [3,2])
C1879313 (UMLS CUI [3,3])
Glucagon-Like Peptide-1 Receptor agonists | Dipeptidyl-Peptidase IV Inhibitors
Item
treatment with glucagon-like peptide (glp)-1 receptor agonists or with dipeptidyl peptidase (dpp)-iv inhibitors
boolean
C0378073 (UMLS CUI [1,1])
C0243192 (UMLS CUI [1,2])
C1827106 (UMLS CUI [2])
Proliferative diabetic retinopathy | Light Coagulation | Operative Surgical Procedures | Retinal Disease Unstable Rapidly progressive | Slit lamp fundus examination
Item
active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (an optic fundus examination should have been performed in the 2 years prior to study entry)
boolean
C0154830 (UMLS CUI [1])
C0023694 (UMLS CUI [2])
C0543467 (UMLS CUI [3])
C0035309 (UMLS CUI [4,1])
C0443343 (UMLS CUI [4,2])
C1838681 (UMLS CUI [4,3])
C1444586 (UMLS CUI [5])
Pregnancy | Childbearing Potential Pregnancy test negative | Childbearing Potential Contraceptive methods
Item
pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraceptive method)
boolean
C0032961 (UMLS CUI [1])
C3831118 (UMLS CUI [2,1])
C0427780 (UMLS CUI [2,2])
C3831118 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
Breast Feeding
Item
breast-feeding
boolean
C0006147 (UMLS CUI [1])
Hypersensitivity Investigational New Drugs | Hypersensitivity Pharmaceutical Preparations Chemical Structure Similar
Item
history of hypersensitivity to the study drugs or to drugs with a similar chemical structure
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C0220807 (UMLS CUI [2,3])
C2348205 (UMLS CUI [2,4])
CORTICOSTEROIDS FOR SYSTEMIC USE
Item
treatment with systemic corticosteroids in the 3 months prior to study entry
boolean
C3653708 (UMLS CUI [1])
Investigational New Drugs
Item
treatment with any investigational product in the 2 months prior to study entry
boolean
C0013230 (UMLS CUI [1])
Probability Illicit drug use Patient need for
Item
likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
boolean
C0033204 (UMLS CUI [1,1])
C0281875 (UMLS CUI [1,2])
C0686904 (UMLS CUI [1,3])
Cardiovascular Disease | Liver disease | nervous system disorder | Endocrine System Disease | Disease Major Protocol Compliance Difficulty | Disease Major Research results Difficulty
Item
clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult
boolean
C0007222 (UMLS CUI [1])
C0023895 (UMLS CUI [2])
C0027765 (UMLS CUI [3])
C0014130 (UMLS CUI [4])
C0012634 (UMLS CUI [5,1])
C0205164 (UMLS CUI [5,2])
C0525058 (UMLS CUI [5,3])
C0332218 (UMLS CUI [5,4])
C0012634 (UMLS CUI [6,1])
C0205164 (UMLS CUI [6,2])
C0683954 (UMLS CUI [6,3])
C0332218 (UMLS CUI [6,4])
Liver Dysfunction | Alanine aminotransferase increased | Aspartate aminotransferase increased
Item
impaired hepatic function as shown by alamine aminotransferase (alt) and/or aspartate aminotransferase (ast) greater than three times the upper limit of normal range at study entry
boolean
C0086565 (UMLS CUI [1])
C0151905 (UMLS CUI [2])
C0151904 (UMLS CUI [3])
Renal Insufficiency | Creatinine measurement, serum | Gender
Item
impaired renal function as shown by serum creatinine ≥ 1.5 mg/dl (≥ 133 μmol/l) in men and ≥ 1.4 mg/dl (124 μmol/l) in women at study entry
boolean
C1565489 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
C0079399 (UMLS CUI [3])
Substance Use Disorders
Item
history of drug or alcohol abuse in the last year
boolean
C0038586 (UMLS CUI [1])
Study Subject Participation Status
Item
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
boolean
C2348568 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial